Head and Neck Cancer

Strategies for Managing Postradiotherapy Cerebral Radiation Necrosis in Nontarget Brain Tissue

By

Bryant Furlow

Publish Date December 11, 2019

This review seeks to shed light on a relatively common but poorly understood adverse effect of radiotherapy for primary and metastatic brain or head and neck tumors.

Pembrolizumab Prolongs Survival in Advanced Head, Neck Cancer

Publish Date November 25, 2019

Authors recommend pembrolizumab, with or without chemotherapy, as first-line treatment.

The Disappointing Reality of Crowdfunding Cancer Care

By

Sarah Elizabeth Richards

Publish Date October 22, 2019

If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.

Some Targeted Therapies May Miss the Mark

By

Caroline Seydel

Publish Date October 17, 2019

Ten different drugs continued to kill cancer cells even when their target proteins were removed.

Incidence of HPV-Positive Head and Neck Cancer Up in the U.S.

Publish Date October 4, 2019

From 2013 to 2014, incidence of HPV-positive oropharyngeal cancers was 4.62 per 100,000 persons.

Delaying Treatment Worsens Head, Neck Cancer Outcomes

Publish Date September 20, 2019

Findings show that survival declines, recurrence increases with delays of more than 60 days.

Which Feeding Tubes Do Head and Neck Cancer Clinicians Prefer to Use in Patients Undergoing Radiotherapy?

By

Susan Moench, PhD, PA-C

Publish Date September 13, 2019

Nasogastric tubes placed reactively or gastrostomy tubes placed prophylactically? Head and neck cancer experts weigh in on which they, and their patients, prefer to use.

Comparison Study Shows Predictive Value for CSCC of the Head and Neck of BWH vs AJCC 8

By

John Schieszer

Publish Date August 29, 2019

A team of researchers sought to determine if BWH Tumor Classification System classified tumors more accurately than AJCC 8, and their sensitivity and specificity for predicting poor outcomes.

Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval

By

Brian Park, PharmD

Publish Date August 16, 2019

The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)

Factors Associated With Thyroid Cancer Overtreatment Identified

Publish Date July 26, 2019

Overtreatment more likely in younger, male, Hispanic or Asian patients, those with extensive lymph node surgery.